Clinical association between primary hyperparathyroidism and multiple myeloma

Authors

  • Pedro Javier Machural de la Torre Hospital Universitario "General Calixto García", Departamento de Nefrología, Universidad de Ciencias Médicas de La Habana, Facultad de Ciencias Médicas "Calixto García". La Habana, Cuba. https://orcid.org/0009-0007-7608-4182
  • Eisy Cabrera Vazquez Hospital Universitario "General Calixto García", Departamento de Nefrología, Universidad de Ciencias Médicas de La Habana, Facultad de Ciencias Médicas "Calixto García". La Habana, Cuba. https://orcid.org/0009-0007-4360-0806
  • Greidy Surera Rodríguez Hospital General "Camilo Cienfuegos", Departamento de Nefrología, Universidad de Ciencias Médicas de Sancti Spíritus, Facultad de Ciencias Médicas "Dr. Faustino Pérez Hernández". Sancti Spíritus, Cuba. https://orcid.org/0000-0003-3675-6347

Keywords:

Primary hyperparathyrioidism; multiple myeloma; patients

Abstract

Introduction: Primary hyperparathyroidism and multiple myeloma are two common causes of hypercalcemia. In turn, hypercalcemia is divided into two categories: that associated with abnormalities of the parathyroid gland, and that where hypercalcemia appears despite adequate suppression of the parathyroid gland.
Objective: To determine a possible association between primary hyperparathyroidism and multiple myeloma in a patient.
Clinical case: A 53-year-old female patient who started with acute kidney injury, and was diagnosed with an association between primary hyperparathyroidism and multiple myeloma. Severe hypercalcemia and acute kidney injury were the common presenting clinical features.
Conclusions: In this patient with acute renal failure, the clinic pathological correlation between Primary hyperparathyroidism and multiple myeloma was demonstrated.

Downloads

Download data is not yet available.

References

1. Dai X, Chen S, Yang X. Temporal trend sand demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER data base (1999-2022). Blood Cancer J. 2026;16:[aprox. 8p]. [access: 24/04/2026]. Availble from: https://doi.org/10.1038/s41408-026-1577-w

2. Moraes Hungria VT, Peña C, Gómez-Almaguer D, Martínez-Cordero H, Schütz NP, Blunk V. Multiple myeloma in Latin America: a systematic review. EJ Haem. 2024;5(4):867-78. [access: 24/04/2026]. Available from: https://doi:10.1002/jha2.905

3. Ramón Rodríguez LG, Rivera Keeling C, Arencibia Núñez A, Avila Cabrera OM, Izquierdo Cano L, Espinosa-Estrada Edgardo, et al. Caracterización clínica y de laboratorio del mieloma múltiple en el Instituto de Hematología e Inmunología. Rev cubana Hematol Inmunol Hemoter [Internet]. 2013;29(4):382-97. [acceso: 24/04/2026]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892013000400008&lng=es

4. Bove V, Riva E, Vasquez J, Pena C, Nunes R. Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Latin America. JCO Glob Oncol. 2022;8:e2200068. [access: 24/04/2026]. Available from: https://doi.org/10.1200/GO.22.00068

5. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Work shop. JBone Miner Res. 2022;37(11):2293-314. [access: 24/04/2026]. Available from: https://doi:10.1002/jbmr.4677

6. Palermo A, Tabacco G, Makras P, Zavatta G, Trimboli P, Castellano E, et al. Primary hyperparathyroidism: from guide linest out patient clinic. Rev Endocr Metab Disord. 2024;25(5):875-96. [access: 24/04/2026]. Available from: https://doi.org/:10.1007/s11154-024-09899-5

7. Wu C, Gillis A, Lindeman B, Chen H, Fazendin J. Normocalcemic primary hyperparathyroidism: from pathophysiology to clinical management. Am J Surg. 2024;235:115812. [access: 24/04/2026]. Available from: https://doi.org/:10.1016/j.amjsurg.2024.115812

8. Salmon MK, Fritz CG, Barrette LX, Romeo D, Suresh NV, Ng JJ, et al. Quality appraisal of clinical practice guidelines for the evaluation and management of primary hyperparathyroidism. Endocrine. 2024;85(2):864-72. [access: 24/04/2026]. Available from: https://doi.org:10.1007/s12020-024-03790-8

9. Olivera Fajardo D, Puerto Lorenzo J, Torres Ajá L. Adenoma paratiroideo. Presentación de un caso. Medisur [Internet]. 2016;14(5):567-72. [acceso: 24/04/2026]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2016000500013&lng=es

10. Notarfranchi L, Marchica V, Dalla Palma B, Pelagatti L, Burroughs-Garcia J, Pedrazzoni M, et al. Concomitant primary hyperparathyroidism in patients with multiple myeloma: a possible link? Acta Haematologica. 2021;144(3):302-7. [access: 4/07/2025]. Available from: https://doi.org/10.1159/000509768

11. Arnulf B, Bengoufa D, Sarfati E, Toubert ME, Meignin V, Brouet JC, et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism:a prospective study. Arch Intern Med. 2002;162(4):464-67. [access: 22/07/26]. Available from: https://doi.org/10.1001/archinte.162.4.464

12. Yeo PS. Multiple myeloma and primary hyperparathyroidism: a case of dual pathologies co-existing for the presentation of hypercalcaemia. European Journal of Endocrinology. 2026;195(1):839. DOI:10.1093/ejendo/lvag096.839

13. Somogyi A, Berta E, Lengyel I, Váróczy L,Nagy EV,Bodor M. Concomitant multiple myeloma in a patient with primary hyperparathyroidism. Endocrine Abstracts. 2024;99:EP1317. [access: 14/06/2026] Available from: https://doi.org/10.1530/endoabs.99.EP1317

14. Double Hit of Primary Hyperparathyroidism and Multiple Myeloma Causing Severe Hypercalcemia. Endocrine Practice. 2025;31(9):S153. [access: 2/05/2025]. Available from: https://doi.org doi/10.1016/j.eprac.2025.05.420

15. Malard F, Neri P, Bahlis NJ,.Multiple myeloma. Nat Rev Dis Primers. 2024;10:45. [access: 14/06/2025] Available from: https://doi.org/10.1038/s41572-024-00529-7

16. Maura F, Bergsagel PL. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications. Hematol Oncol Clin North Am. 2024;38(2):267-79. DOI: 10.1016/j.hoc.2023.12.010.

17. Zhao H. Pathogenesis and treatment of myeloma-related bone disease. Front Endocrinol (Lausanne). 2022;13:834238. [access: 07/05/2026]. Available from: https://doi.org/10.3389/fendo.2022.834238

18. Bernstein ZS, Kim EB, Raje N. Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. Cells. 2022;11(15):2308. [access: 8/03/2026]. Available from: https://doi.org/10.3390/cells11152308

19. Zhang F, Zhuang J. Pathophysiology and therapeutic advances in myeloma bone disease. Chronic Dis Transl Med. 2022;8(4):264-70. [access: 9/05/2026]. Available from: https://doi.org /10.1002/cdt3.35

20. Pacheco J, Guerrero Y, Pedrique G, Pérez J, Zerpa Y. Manejo de pacientes con hipoparatiroidismo: Guías clínicas del Servicio de Endocrinología del Instituto Autónomo Hospital Universitario de Los Andes. Rev. Venez. Endocrinol. Metab. [Internet]. 2014;12(3):204-13. [acceso: 9/05/2026]. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1690-31102014000300008&lng=es

21. Tsai SH, Kan WC, Jhen RN, Chang YM, Kao JL, Lai HY, et al. Secondary hyperparathyroidism in chronic kidney disease: a narrative review focus on therapeutic strategy. Clin Med (Lond). 2024;24(5):100238. Available from: https://doi.org/10.1016/j.clinme.2024.100238

22. Magagnoli L, Ciceri P, Cozzolino M. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs. Expert Opin Investig Drugs. 2024;33(8):775-89. [access: 9/07/2026]. Available from: https://doi.org/10.1080/13543784.2024.2369307

23. Rodzo·-Norwicz M, Norwicz S, Sowa-Ku·ma M, Gala-B··dzi·ska A. Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities. Endokrynol Pol. 2023;74(5):490-98. DOI: 10.5603/ep.95820.

24. KDIGO. KDIGO 2024 Clinical Practice Guideline forth e Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. [acceso: 17/04/2026]. Available from: https://doi.org/10.1016/j.kint.2023.10.018

Downloads

Published

2026-09-01

How to Cite

1.
Machural de la Torre PJ, Cabrera Vazquez E, Surera Rodríguez G. Clinical association between primary hyperparathyroidism and multiple myeloma. Arch Hosp Univ "Gen Calixto García” [Internet]. 2026 Sep. 1 [cited 2026 Nov. 4];14(2). Available from: https://revcalixto.sld.cu/index.php/ahcg/article/view/1676

Issue

Vol. 14 No. 2 (2026): mayo - agosto

Section

Presentación de Casos

License

Copyright (c) 2026 Pedro Javier Machural de la Torre, Eisy Cabrera Vazquez, Greidy Surera Rodríguez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Atribución– No Comercial 4.0 que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada.